We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Ask ADVFN Intelligence (AI)
-- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and...
MENLO PARK, Calif. and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV) and Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) announced today that they have entered into a...
Moore Kuehn Encourages FTSV, MINI, POPE, WAAS, and TLRA Investors to Contact Law Firm PR Newswire NEW YORK, March 4, 2020 NEW YORK, March 4, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a securities...
SHAREHOLDER ALERT: WeissLaw LLP Investigates Forty Seven, Inc. PR Newswire NEW YORK, March 3, 2020 NEW YORK, March 3, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of...
By Joseph Walker This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal (March 3, 2020...
By Colin Kellaher Shares of Forty Seven Inc. rose more than 60% in early trading Monday after the immuno-oncology company agreed to be acquired by Gilead Sciences Inc. for about $4.9 billion...
(FTSV) Alert: Johnson Fistel Investigates Proposed Sale of Forty Seven, Inc.; Are Shareholders Getting a Fair Deal? PR Newswire SAN DIEGO, March 2, 2020 SAN DIEGO, March 2, 2020 /PRNewswire/...
By Colin Kellaher Gilead Sciences Inc. on Monday said it agreed to buy Forty Seven Inc. for about $4.9 billion in a deal that boosts its immuno-oncology portfolio. Gilead said it will pay $95.50 a...
– Gilead Gains Forty Seven’s Investigational Immuno-Oncology Therapy in Multiple Clinical Studies for Diseases Including Myelodysplastic Syndrome, Acute Myeloid Leukemia and Diffuse Large B-Cell...
MENLO PARK, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
